According to the Zhitong Finance App, Yao Ming Kangde (02359.HK) issued an announcement on matters relating to the sale of Shanghai Pharmaceutical and Gao Lin's purchase of all shares of Kangde Hongyi and Jinshi Pharmaceutical. As of the date of this announcement, Shanghai Yao Ming has received the first transfer consideration of RMB 1.54 billion, paid in full from Gao Lin in accordance with the share transfer agreement. The delivery prerequisites agreed in the equity transfer agreement have been met, the transaction has been completed, and Kangde Hongyi and Jinshi Pharmaceutical are no longer included in the scope of the Company's consolidated statement. Kangde Hongyi, Jinshi Pharmaceutical and other relevant parties will handle the transaction involving Kangde Hongyi and Jinshi Pharmaceutical's share change registration procedures in accordance with the equity transfer agreement, and it is expected that the change registration will be completed by December 31, 2025.

According to the Zhitong Finance App, Yao Ming Kangde (02359.HK) issued an announcement on matters relating to the sale of Shanghai Pharmaceutical and Gao Lin's purchase of all shares of Kangde Hongyi and Jinshi Pharmaceutical. As of the date of this announcement, Shanghai Yao Ming has received the first transfer consideration of RMB 1.54 billion, paid in full from Gao Lin in accordance with the share transfer agreement. The delivery prerequisites agreed in the equity transfer agreement have been met, the transaction has been completed, and Kangde Hongyi and Jinshi Pharmaceutical are no longer included in the scope of the Company's consolidated statement. Kangde Hongyi, Jinshi Pharmaceutical and other relevant parties will handle the transaction involving Kangde Hongyi and Jinshi Pharmaceutical's share change registration procedures in accordance with the equity transfer agreement, and it is expected that the change registration will be completed by December 31, 2025.